Q-omics provides the consensus-scored ALOX12B profile across patient tissues and cancer cell-line models. ALOX12B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, ALOX12B is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, ALOX12B RNA expression shows 12,551 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KIRC, and TGCT as cancer lineages where ALOX12B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ALOX12B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ALOX12B survival associations across molecular data types. ALOX12B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (10) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ALOX12B RNA expression–survival associations across cancer types. High ALOX12B expression shows unfavorable associations in UCEC, COAD and SKCM, but favorable associations in KIRC, CESC and LGG. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for ALOX12B RNA expression.
This table summarizes ALOX12B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ALOX12B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ALOX12B shows lower tumor expression in KICH and COAD and higher tumor expression in KIRC, THCA, LUSC and CHOL. The KIRC box plot shows higher ALOX12B RNA expression in tumor versus normal tissue (log2 FC = +0.564, t-test p < 0.001).
This table shows molecular features associated with ALOX12B in patient tissues and cancer cell lines. In patient samples, ALOX12B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ALOX12B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SOFT_TISSUE.
